
Roche acquires Telavant Holdings to win TLA1 race
The takeover of Telavant, a 75:25 jont-venture of Roivant Sciences and the US pharmaceutical group Pfizer, however, may cost Roche up to US-$7.25bn....

Antiverse and GlobalBio Inc. extend collaboration
AI specialist Antiverse Ltd (Cardiff, UK) and antobody engeeniering expert GlobalBio, Inc. (New York, USA) will be extending their collaboration to...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Synerkine Pharma BV secures EUR 12.1m in Series A extension
The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and...

Valnevas Lyme vaccine trial complets recruitment
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. announced that they have completed enrollment in the Vaccine Against Lyme for Outdoor...